STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial
SPRING HOUSE, PENNSYLVANIA, July 9, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented...
Source: Johnson and Johnson - July 9, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Study Estimates Incidence of Dupilumab-Related Conjunctivitis Study Estimates Incidence of Dupilumab-Related Conjunctivitis
The overall incidence rate of conjunctivitis within 6 months of starting treatment was 6.6% in dupilumab users, compared with 3.3% in methotrexate users.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 18, 2021 Category: Drugs & Pharmacology Tags: Dermatology News Source Type: news
Patients Taking Anti-Inflammatory Drugs Respond Less Well to COVID-19 Vaccine
(NYU Langone Health / NYU Grossman School of Medicine) One-quarter of people who take the drug methotrexate for common immune system disorders -- from rheumatoid arthritis to multiple sclerosis -- mount a weaker immune response to a COVID-19 vaccine, a new study shows. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 2, 2021 Category: Infectious Diseases Source Type: news
Methotrexate May Impair Immune Response to mRNA COVID-19 Vaccine
WEDNESDAY, May 26, 2021 -- Patients with immune-mediated inflammatory diseases (IMIDs) receiving background methotrexate have worse humoral and cellular immunogenicity to mRNA COVID-19 vaccines, according to a study published online May 25 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2021 Category: Pharmaceuticals Source Type: news
COVID Vax Response Low in Immune-Mediated Inflammatory Diseases COVID Vax Response Low in Immune-Mediated Inflammatory Diseases
Patients who take methotrexate or rituximab seem to be especially vulnerable.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - May 26, 2021 Category: Infectious Diseases Tags: Rheumatology News Source Type: news
Common Immune Drug Methotrexate May Hamper Response to COVID-19 Vaccine
WEDNESDAY, May 26, 2021 -- A widely used medicine for autoimmune diseases may lower people ' s immune response to the Pfizer mRNA COVID-19 vaccine, a new study suggests.
The drug, called methotrexate, is often given to patients with immune-mediated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 26, 2021 Category: General Medicine Source Type: news
Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve patients with mo...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
High-Dose Methotrexate of No CNS Benefit in High-Risk DLBCL High-Dose Methotrexate of No CNS Benefit in High-Risk DLBCL
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have a greater than 10% risk of central nervous system (CNS) relapse.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 19, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Some Should Stop Methotrexate for 2 Weeks After J & J Vaccine Some Should Stop Methotrexate for 2 Weeks After J & J Vaccine
The National Psoriasis Foundation COVID-19 Task Force now recommends that certain patients on methotrexate consider stopping the drug for 2 weeks after receiving the Johnson& Johnson COVID-19 vaccine.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 1, 2021 Category: Dermatology Tags: Dermatology News Source Type: news
SARS-CoV-2 hijacks two key metabolic pathways to rapidly replicate in host cells
(Brigham and Women's Hospital) Researchers studying cultured cells shortly after infecting them with SARS-CoV-2, now have more insight into the metabolic pathways co-opted by the virus. The findings highlight the potential therapeutic benefit of drugs such as methotrexate, which inhibit folate and one-carbon metabolic pathways appropriated by the virus. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 15, 2021 Category: Infectious Diseases Source Type: news
Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients
Patients taking methotrexate for psoriasis or psoriatic arthritis were at a higher risk of developing liver disease than were patients with rheumatoid arthritis on methotrexate.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - February 26, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news
MTX Decreases Tenofovir Exposure in ART-Suppressed HIV MTX Decreases Tenofovir Exposure in ART-Suppressed HIV
A new study finds that methotrexate may alter tenofovir exposure among virally suppressed people living with HIV. Does this warrant a change in dosing during the co-administration of these drugs?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 30, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
RA Remission? Stop Methotrexate, Keep Etanercept RA Remission? Stop Methotrexate, Keep Etanercept
In patients with RA whose disease is well controlled by methotrexate and etanercept, withdrawal of methotrexate led to long-term outcomes that were nearly as good as continuation of combination therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 24, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news
After Methotrexate Failure, Is JAK Inhibitor or Biologic Next? After Methotrexate Failure, Is JAK Inhibitor or Biologic Next?
What is the next step in treatment after a person with rheumatoid arthritis fails to adequately respond to methotrexate -- a Janus kinase inhibitor or a biologic?Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 23, 2020 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
Methotrexate and HCQ Split on Cardiovascular Outcomes in RA Methotrexate and HCQ Split on Cardiovascular Outcomes in RA
No significant differences in major adverse cardiovascular events emerged between methotrexate and hydroxychloroquine treatment in a comparison of adults 65 years or older with rheumatoid arthritis.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 13, 2020 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news
